Eos Energy Enterprises Inc vs Revvity Inc — how do they compare? Eos Energy Enterprises Inc trades at $2.53 (market cap $1.01B), while Revvity Inc trades at $154.1 (market cap $16.98B). The key difference: Revvity Inc is far larger — about 16.8× Eos Energy Enterprises Inc's market cap, and Revvity Inc pays a 0.18% dividend while Eos Energy Enterprises Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eos Energy Enterprises Inc for 16 Days and Revvity Inc for 12 Days on average.
| EOSE | RVTY | |
|---|---|---|
Market Cap | $1.01B | $16.98B |
Volume | 39,626,541 | 1,456,900 |
Sector | Industrials | Health |
52-Week High | $19.19 | $157.36 |
52-Week Low | $2.77 | $82.26 |
Typical Hold Time | 16 Days | 12 Days |
Enterprise Value | $1.34B | $19.30B |
Dividend Yield | — | 0.18% |
Signals from Pluang's Aura AI — not financial advice
Eos Energy Enterprises (EOSE) trades at $2.575, down 16.94% in the last session, reflecting ongoing volatility despite positive business developments. The company shows rapid revenue growth with $214M projected for 2026 but faces significant profitability challenges with a -246.76% net income margin. Recent catalysts include an $87M Department of Energy loan advance and a major partnership with Google for a $350M West Virginia energy project announced September 2, 2026.
While analyst consensus remains cautiously optimistic with a $7.10 price target representing 176% upside, the stock carries substantial risk due to persistent losses and high debt-to-asset ratio of 91.87%. The technical picture is bearish with weak momentum, though oversold RSI levels may indicate potential for near-term bounce. Investment appeal hinges on successful execution of production scaling and path to profitability.
RVTY trades at $155.01, up 0.92% with a bullish technical outlook. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid profitability with 54.98% gross margins. Recent developments include new product launches in Europe and strategic acquisitions to expand metabolic disease research capabilities.
The investment case balances premium valuation (P/E 73.15) against consistent execution and growth initiatives. Key risks include China market pressures and margin compression, while analyst consensus remains positive with 52% buy ratings. Upside potential exists if Q3 earnings meet expectations in November.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Eos Energy Enterprises provides long-duration energy storage solutions. Its signature zinc-based batteries are designed for utility-scale applications, helping to stabilize power grids and integrate renewable energy.
Read more on EOSE →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →